Trump's Cannabis Rescheduling: Tax Relief and Regulatory Hurdles for Canopy Growth and Tilray

U.S. President Donald Trump's executive order last year, which reclassified marijuana from Schedule I to Schedule III under the DEA's Controlled Substances Act, primarily impacts medical cannabis users. While this shift removes certain legal risks for patients, the broader recreational market remains in Schedule I, limiting overall industry growth. The move presents both opportunities and challenges for Canopy Growth (NASDAQ: CGC), Tilray Brands (NASDAQ: TLRY), and Green Thumb Industries (OTC: GTBIF).

Tax Relief from Section 280E: A Partial Win

■Rescheduling allows medical cannabis companies to deduct standard business expenses (e.g., rent, utilities, salaries) previously blocked by IRS Section 280E.

■This change could improve cash flow and profitability for firms like Canopy Growth and Tilray, which focus on medical products.

■However, the recreational segment, still classified as Schedule I, continues to face regulatory and tax barriers.

Compliance Costs: The Hidden Burden of Dual Operations

■Companies selling both medical and recreational products must now segregate inventory, sales, and financial reporting under separate regulatory frameworks.

■Increased regulatory oversight and record-keeping adds operational complexity, particularly for smaller operators.

■Green Thumb Industries, as a multi-state operator, faces heightened administrative costs to comply with dual standards.

Market Reaction: Stocks Climb Amid Regulatory Uncertainty

■Canopy Growth and Tilray shares saw short-term gains following the policy announcement.

■Long-term growth prospects remain muted due to the recreational market's unresolved legal status.

■Investors are cautiously optimistic, favoring firms with strong medical product portfolios and scalable compliance strategies.

Dr. Yaman Ege: This regulatory shift mirrors supply chain disruptions seen in semiconductor industries, where partial policy changes create uneven playing fields. While medical cannabis companies gain tax flexibility, the lack of recreational market clarity forces a conservative investment approach. The compliance costs could divert resources from innovation, but firms leveraging automation and blockchain for tracking may gain a competitive edge.